RT Book, Section A1 Kittleson, Michelle M. A1 Patel, Jignesh K. A1 Kobashigawa, Jon A. A2 Fuster, Valentin A2 Harrington, Robert A. A2 Narula, Jagat A2 Eapen, Zubin J. SR Print(0) ID 1161716891 T1 CARDIAC TRANSPLANTATION T2 Hurst's The Heart, 14e YR 2017 FD 2017 PB McGraw-Hill Education PP New York, NY SN 9780071843249 LK accesscardiology.mhmedical.com/content.aspx?aid=1161716891 RD 2024/11/13 AB Despite major advances in the treatment of end-stage heart disease, a sizable number of patients with refractory heart failure (HF), progressive angina, or uncontrolled ventricular arrhythmias cannot be stabilized with medical or interventional/surgical therapy and suffer significant morbidity and mortality.1 In these patients, biological replacement of the heart (cardiac transplantation) has become standard therapy and is widely accepted to improve quality and quantity of life in carefully selected patients. As technologic and engineering advances occur, support or replacement of the heart by mechanical devices (mechanical circulatory support [MCS]) offers additional options for patients with end-stage heart disease as a bridge to recovery, bridge to transplantation, or destination therapy.